Analytical Data
-
Gene name
SPANXB1
- Application
-
Alternative Names
SPANXB1; SPANXB; SPANXB2; SPANXF1; Sperm protein associated with the nucleus on the X chromosome B1; Cancer/testis antigen 11.2; CT11.2; Nuclear-associated protein SPAN-Xb; SPANX-B; SPANX family member B1; SPANX family member F1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NS25
-
Expression Region
1-103 aa
-
AA Sequence
MGQQSSVRRL KRSVPCESNE ANEANEANKT MPETPTGDSD PQPAPKKMKT SESSTILVVR YRRNVKRTSP EELVNDHARE NRINPDQMEE EEFIEITTER PKK
-
Molecular Weight
11.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SPANXB1 is a member of the cancer/testis (CT) antigen family, primarily expressed in malignant tissues and certain testicular cells, making it an appealing target for cancer immunotherapy. This protein is encoded by the SPANBX1 gene and has garnered attention due to its potential involvement in various cancer types, including melanoma, lung cancer, and breast cancer. The expression of SPANXB1 is typically restricted to the germline, which helps maintain immune tolerance in normal tissues while providing a unique target for therapeutic intervention in cancer. Recent studies have focused on the characterization of SPANXB1 recombinant proteins, aiming to elucidate their structural properties and functional roles in tumorigenesis. Developing SPANXB1 as a target for cancer vaccines or monoclonal antibody therapies involves understanding its immunogenicity and interaction with the immune system. This research is further supported by evidence showing that patients expressing SPANXB1 often demonstrate a specific immune response against it, suggesting that targeting this antigen could enhance the efficacy of cancer immunotherapies. As studies continue to reveal the mechanisms by which SPANXB1 contributes to cancer progression, the protein's role as a biomarker for cancer diagnostics and as a target for novel therapeutic strategies is becoming increasingly significant. Thus, the investigation of SPANXB1 recombinant proteins represents a promising avenue in the development of personalized cancer treatments, highlighting the growing importance of cancer/testis antigens in the field of oncology.
